David Haen

David Haen

TMFHaen

Recent articles

GettyImages-1083510246

Is Pfizer a Great Dividend Stock?

A strategic transaction this year will give investors two shots to earn dividends.


GettyImages-664386084

Now’s the Time to Buy These 3 Stocks

These drug developers will give your portfolio a boost.


GettyImages-187921657

3 Top Pharma Stocks to Buy Right Now

Promising new drugs will drive these companies' stocks skyward.


GettyImages-1133974061

Should You Own This Sleeper Biotech Stock?

This cancer-fighting biotech could have two approved drugs in the next year, and a whole lot more.


GettyImages-1138937146

Where Will Adaptimmune Be in 5 Years?

Big pharma partners could help this cutting-edge cell-therapy company be successful in the future.

GettyImages-1216472651

Will GenMark Diagnostics' Stock Keep Rising?

A coronavirus diagnostic test is fueling this biotech's revenue for 2020.


GettyImages-864446614

This Under-the-Radar Drug Developer May Have an Answer for Patients With Severe COVID-19

Third-quarter results from a COVID-19 trial could send this stock soaring.


GettyImages-1201544365

Is There A Safer Way to Invest in a Coronavirus Vaccine?

Size may matter in the long run.


GettyImages-1169106100

Is Axsome Therapeutics a Screaming Buy?

Two positive late-stage clinical trials may just be the beginning.


GettyImages-1129797106

If You Invested $10,000 in Amarin's IPO, This Is How Much Money You'd Have Now

Not all IPO returns are equal.

GettyImages-187921657

Should You Buy Global Blood Therapeutics Before This Week's Earnings?

On Wednesday, investors will learn the progress of its sickle cell disease drug launch.


GettyImages-508544108

AstraZeneca Notches Win with Prostate Cancer Drug

New clinical trial results may lead to a label expansion this quarter for Lynparza, and huge revenue growth for the drug.


GettyImages-1142997722

Did Merck Just Receive a Gift From the FDA?

A new, more convenient dosing schedule favors Keytruda.


GettyImages-536688016

Better Buy: Illumina vs. Adaptive Biotechnologies

One company has a well-established line of products that made it the leader in its niche, but the other has a bold vision about how to use them.


GettyImages-1207501947

Should You Buy Stock Now in This New Coronavirus Drug Developer?

This company's repurposed cancer drug might help patients with severe COVID-19.

GettyImages-618344178

Will Last Week's Biotech IPO Outperform in a Recession?

This cancer drug developer will have smooth sailing ahead -- at least until it reports clinical trial results next year.


GettyImages-1162987377

Myovant Squares Off with AbbVie On Endometriosis Treatment

With positive clinical trial results and a confirmatory study expected to report this quarter, investors should dig in.


GettyImages-1219784934

Better Buy: AnaptysBio vs. Exelixis

Key clinical trial results this quarter will determine the better buy.


GettyImages-1129797106

These 3 Biotechs Had Successful IPOs During the Coronavirus Crisis. Are They Buys?

These companies just raised significant cash to advance promising drug pipelines.


GettyImages-1096306446

Could CVS Health Be a Millionaire-Maker Stock?

Investors seek to capitalize on one of the broadest-reaching companies in healthcare.